Autres langues Axsome Therapeutics, Inc.

Actions

AXSM

US05464T1043

Temps réel estimé Cboe BZX Autres places de cotation 18:39:12 30/04/2024			Varia. 5j.	Varia. 1 janv.
74,52 ^USD	+1,12 %		+2,19 %	-6,17 %

29/04	L'essai de phase 3 d'Axsome Therapeutics sur le traitement de la maladie d'Alzheimer est très risqué et très rémunérateur, selon Morgan Stanley	MT
29/04	AXSOME THERAPEUTICS, INC. : Morgan Stanley relève à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

North American Morning Briefing : More Earnings -2-	12:18
Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says	29/04
Axsome Therapeutics highlights innovative neuroscience portfolio at the american academy of neurology 2024 annual meeting	16/04
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting	15/04
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting	15/04
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6	10/04
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	02/04
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	01/04
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	01/04
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment	25/03
Axsome Therapeutics : AXS-12 SYMPHONY Results - Slides	25/03
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	25/03
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	25/03
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial	25/03
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy	25/03
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy	25/03
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	19/03
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	19/03
Axsome Therapeutics Insider Sold Shares Worth $2,257,449, According to a Recent SEC Filing	18/03
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Axsome Therapeutics, Inc.

Actions

AXSM

US05464T1043

Autres langues

Filtres